For US Healthcare Professionals only

Patient support for WAYRILZ™

HemAssist complements the care you provide your patients with support for what’s ahead.


Getting started with WAYRILZ

HemAssist works with you and your patients to get them started on WAYRILZ as efficiently as possible. Our support begins with the enrollment process. As soon as we receive an enrollment form, we can begin a benefits investigation to determine if your patient is eligible for financial assistance.

From there, our support includes triaging the prescription to the patient's specialty pharmacy, assisting with medication shipments, supporting your office with claims and reimbursements, and more.

WAYRILZ™ (rilzabrutinib) logo

Our support

Decorative wallet icon

Affording WAYRILZ

No matter your patient's situation, we are committed to helping them access and afford WAYRILZ. The HemAssist team will verify your patient's insurance coverage and determine what financial assistance programs they may be eligible for.

Decorative 1-2-3 steps icon

Starting treatment

The HemAssist team can help your patient get started with WAYRILZ right away. This includes reviewing how WAYRILZ works, what to do when they miss a dose, and how to track when they’ve taken treatment.

Decorative conversation bubble icon

Ongoing support

Our team provides support and guidance to your patient throughout the WAYRILZ journey. This includes helping patients stay on their treatment schedule and providing ITP education.

Financial assistance

HemAssist works directly with your patients to help identify programs they may be eligible for.

Copay Assistance Program*

HemAssist may be able to help eligible patients gain access to WAYRILZ for as little as $0 copay per fill.

Free Trial Program†

Patients can receive their first month supply of treatment with an enrollment form and valid prescription.

Patient Assistance Program†

HemAssist's Patient Assistance Program may be available to help eligible WAYRILZ patients who are uninsured, underinsured, or experiencing a temporary loss of insurance coverage.

*Not valid if the patient is utilizing a state or federally funded health insurance program such as Medicare (including Medicare Part D), Medicaid, Medigap, VA, DoD, TRICARE®, state pharmaceutical assistance program, etc. to pay in part or in full for their WAYRILZ prescription. Not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Copay Program at any time without notice. Savings by patients may vary depending on their out-of-pocket costs. The program is intended to help patients afford their WAYRILZ prescription. Patients may have insurance plans that attempt to dilute the impact of the assistance available under the program. In those situations, the program may change its terms.

†Free Trial valid only for a patient’s first prescriptions and it is limited to one use per patient per product for their lifetime. Free Trial not valid in Vermont. Claims for free products dispensed through the Free Trial or Patient Assistance Programs shall not be submitted to any third-party payer, public or private (e.g. private insurance, Medicaid, Medicare, VA, DoD, TRICARE®, or similar federal or state programs) for reimbursement. All Programs not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Programs at any time without notice. Program details provided upon registration.

Meet your team

HemAssist works directly with your patients to help identify programs they may be eligible for.

HemAssist team member sitting at a desk with a headset

Clinical Educator (CE)

CEs can answer questions about ITP and WAYRILZ and can provide helpful support to your patients including how treatment works, how to track treatment, and ongoing support.

Portrayal of a smiling man sitting at a desk wearing a headset

Case Managers

Our dedicated Case Managers will provide personalized insurance investigations and answer specific questions about financial assistance options for eligible patients.

Portrayal of an woman in an office speaking into a headset

Field Reimbursement Managers (FRM)

Our FRMs can help you navigate insurance coverage and provide reimbursement education and solutions.

Ready to enroll a patient in HemAssist?

It takes just a few steps. Enroll online or download and fax an enrollment form. 

INDICATION

WAYRILZ is indicated for the treatment of adult patients with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.  

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Serious Infections: An increased risk of serious infections (including bacterial, viral, or fungal) can occur in patients treated with Bruton’s tyrosine kinase (BTK) inhibitors, including WAYRILZ. Fatal pneumonia occurred in one participant treated with WAYRILZ in the LUNA-3 trial. Other serious infections [one each (0.8%)] included COVID-19 infection, wound infection, urinary tract infection and kidney abscess. Monitor patients for signs and symptoms of infection and treat appropriately.

Hepatotoxicity, Including Drug-Induced Liver Injury (DILI): Hepatotoxicity, including severe, life-threatening, and potentially fatal cases of DILI, can occur in patients treated with BTK inhibitors. Elevations of liver transaminases occurred with WAYRILZ in the ITP clinical trials and were generally mild to moderate in severity. Evaluate bilirubin and transaminases at baseline and as clinically indicated during treatment with WAYRILZ. For patients who develop abnormal liver tests after WAYRILZ, monitor more frequently. If DILI is suspected, withhold WAYRILZ. Upon confirmation of DILI, discontinue WAYRILZ.

Embryo-Fetal Toxicity: Based on findings from preliminary animal reproduction studies, WAYRILZ may cause fetal harm when administered to a pregnant woman. Verify pregnancy status of females of reproductive potential prior to initiating WAYRILZ treatment. Advise females of reproductive potential to use effective contraception while taking WAYRILZ and for 1 week after the final dose.

ADVERSE REACTIONS

Most common adverse reactions reported (incidence ≥10%) were diarrhea, nausea, headache, abdominal pain, and COVID-19.

DRUG INTERACTIONS

  • Avoid concomitant use of WAYRILZ with strong or moderate CYP3A inhibitors, which increases the risk of WAYRILZ adverse reactions. If short term use of these inhibitors cannot be avoided, interrupt treatment with WAYRILZ. Avoid concomitant use of grapefruit, starfruit and products containing these fruits, and Seville oranges with WAYRILZ.
  • Avoid concomitant use with a strong or moderate CYP3A inducer, which may reduce WAYRILZ efficacy.
  • Administer the dose of WAYRILZ at least 2 hours before administration of an antacid or histamine H2 receptor antagonist. Avoid concomitant use of proton pump inhibitors with WAYRILZ. Concomitant use of acid reducing agents may reduce WAYRILZ efficacy.
  • Rilzabrutinib is a moderate inhibitor of CYP3A and increases exposure of these substrates. Monitor for adverse reactions and consider dosage adjustment of the CYP3A substrate.
  • Rilzabrutinib is an inhibitor of P-gp, BCRP and OATP1B in vitro. The effect of concomitant use of WAYRILZ with OATP1B and BCRP substrates has not been established in clinical studies. Monitor for adverse reactions of the concurrently administered P-gp, BCRP, or OATP1B substrate more frequently where minimal substrate concentration changes may lead to serious adverse reactions.

USE IN SPECIFIC POPULATIONS

  • Lactation: Due to the potential for adverse reactions in a breastfed child, advise lactating women not to breastfeed while taking WAYRILZ and for at least 1 week after the final dose
  • Hepatic Impairment: Avoid administration of WAYRILZ in patients with moderate or severe hepatic impairment (Child-Pugh class B-C)
  • Renal Impairment: Avoid use in patients with severe renal impairment

INDICATION

IMPORTANT SAFETY INFORMATION

HemAssist Sanofi Support Here for your patients throughout their treatment journey. Call 1-833-723-5463 Monday – Friday 8 AM to 7 PM ET Fax 1-855-398-7634 © 2025 Sanofi. All rights reserved. WAYRILZ, HemAssist, and Sanofi are trademarks of Sanofi or an affiliate. All other trademarks are the property of their respective owners. MAT-US-2504818-v1.0-08/2025